Nasdaq auph.

Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.

Nasdaq auph. Things To Know About Nasdaq auph.

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ...These stocks are American Woodmark Corporation (NASDAQ:AMWD), Great Western Bancorp Inc (NYSE:GWB), SEMrush Holdings, Inc. (NYSE:SEMR), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), Addus Homecare ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) is a company that specializes in developing treatments for diseases that currently have few treatment options. They focus on autoimmune, kidney, and rare ...Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike.Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ...October 30, 2023 at 7:26 AM · 3 min read We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH) business as it appears the company …

Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not …Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the ...Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ...

AUPH: The Nasdaq Global Market LLC: AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES. TABLE OF CONTENTS. Page: PART I. FINANCIAL INFORMATION. 1. Item 1. Financial Statements (Unaudited) 1. Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2023 and December 31, 202 2. 1.

The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ...

View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...The 2023 Bull Market Was a Lie. Quant Ratings Updated on 122 Stocks. Gibraltar Industries (FRA:GI2) Price Target Increased by 22.49% to 80.15. Shiba Inu (SHIB) Price Rally Eyes $0.000020 as Buyers ...Given this risk, we thought we'd take a look at whether Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders should be worried about its cash burn. …SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ...

1 day ago · Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike. What happened. Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price ...Sep 18, 2023 · NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ... Dec 1, 2023 · View Aurinia Pharmaceuticals Inc AUPH investment & stock information. Get the latest Aurinia Pharmaceuticals Inc AUPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Playstudios, Twitter, Aurinia, and Stronghold and Encourages Investors to Contact the Firm

AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.

Aurinia Pharmaceuticals (NASDAQ:AUPH) Third Quarter 2022 ResultsKey Financial Results. Revenue: US$55.8m (up 280% from 3Q 2021). Net loss: US$8.99m (loss narrowed by 82% from 3Q 2021). US$0.063 ...See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. AUPH's current price target is …Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ... Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... The 2023 Bull Market Was a Lie. Quant Ratings Updated on 122 Stocks. Gibraltar Industries (FRA:GI2) Price Target Increased by 22.49% to 80.15. Shiba Inu (SHIB) Price Rally Eyes $0.000020 as Buyers ...NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Aurinia Pharmaceuticals (NASDAQ: AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ: BIIB) could potentially look to target the company. Aurinia ( AUPH ...Price. 9.06. +4.86%. Webull offers AUPH Ent Holdg (AUPH) historical stock prices, in-depth market analysis, NASDAQ: AUPH real-time stock quote data, in-depth charts, free AUPH options chain data, and a fully built financial calendar to help you invest smart. Buy AUPH stock at Webull.

December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session.

Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% Upside

Shares of the autoimmune disease specialist Aurinia Pharmaceuticals ( AUPH -1.04%) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price cratered by more ...AUPH: The Nasdaq Global Market LLC: AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES. TABLE OF CONTENTS. Page: PART I. FINANCIAL INFORMATION. 1. Item 1. Financial Statements (Unaudited) 1. Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2023 and December 31, 202 2. 1.See historical performance and comparison. View Valuation. Research Aurinia Pharmaceuticals' (Nasdaq:AUPH) stock price, latest news & stock analysis. Find …Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the ...To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not …Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors? Perusahaan melaporkan laba per saham sebesar $-0,09 dan pendapatan sebesar $40,8M. Survei EPS dari analis Investing.com diharapkan sesuai perkiraan yang dirilis sebesar $-0,17 dengan laba $38,44M. Untuk tahun ini, saham Aurinia Pharma naik 65%, unggul kuat Nasdaq yang naik 24% dalam setahun hingga hari ini.ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AUPH March 18, 2022 13:00 ET | Source: The Rosen ...

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...December 4, 2023. Technologies. Vertex Energy Inc (NASDAQ:VTNR) has a beta value of 1.68 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $348.79M, closed the recent trade at $3.73 per share which meant it gained $0.11 on the day or 3.04% during that session.Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.Instagram:https://instagram. high leverage forex brokersoptions trading softwarecenterpoint securities reviewoption brokers October 30, 2023 at 7:26 AM · 3 min read We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH) business as it appears the company …Aug 18, 2021 · Aurinia AUPH announced that it has acquired two new pipeline candidates, which will target rare autoimmune and kidney-related diseases. Both the candidates, renamed as AUR200 and AUR300 following ... pins quotetrading.scottrade.com Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that... nyse flng The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ...